IDYA

IDEAYA is a clinical-stage precision oncology company whose FY2025 revenue of $219M (up from $7M in FY2024) is not commercial product revenue but a one-time-flavored upfront from the August 2025 Servier ex-US license for darovasertib ($210M upfront, plus up to $320M in milestones and double-digit royalties). The MD&A makes clear this is a licensing/collaboration windfall, not a recurring top line — so the trailing 14.6x P/S is essentially meaningless and should not be used to justify the $3.19B market cap. The real question is the pipeline.

The fundamentals show a company that has cleaned up its burn meaningfully: operating cash outflow narrowed from -$247.6M in FY2024 to -$71.1M in FY2025 (a $176M improvement, almost entirely the Servier upfront), and net loss improved 58.6% YoY to -$114M. R&D still ran at $315M, so the underlying burn ex-Servier is still heavy. The balance sheet is the bright spot: $1.11B in assets, only $86.4M in liabilities, L/E of 0.08x, $113M cash plus a large marketable-securities book (note the $680M of maturities and $608M of repurchases in investing activities) — this is a well-capitalized biotech with multi-year runway and minimal debt risk.